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Intestinal fibrosis is an incurable complication of Crohn’s disease
involving increased numbers of collagen-producing myofibro-
blasts. Tumor necrosis factor (TNF)has defined proinflammatory
roles in Crohn’s disease but its role in fibrosis is unclear. We tested
thehypothesis thatTNF increases collagen accumulation andpro-
liferation in intestinal myofibroblasts and has additive effects in
combination with insulin-like growth factor (IGF) I. The mecha-
nisms, TNF receptor isoform, and downstream signaling pathways
were examined. Intestinal myofibroblasts from wild-type (WT)
mice or mice homozygous for disruption of genes encoding TNFR1
(TNFR1/), TNFR2 (TNFR2/), or both (TNFR1/2/), were
treated with TNF, IGF-I, or both. In WT cells, TNF and IGF-I
stimulated type I collagen accumulation and DNA synthesis in an
additive manner. IGF-I, but not TNF, stimulated type I collagen
gene activation. TNF, but not IGF-I, induced tissue inhibitor of
metalloproteinase-1 (TIMP-1) expression and reducedmatrixmet-
alloproteinases-2 activity and collagendegradation.TNF also acti-
vated ERK1/2. These responses to TNF were absent in TNFR2/
and TNFR1/2/ myofibroblasts, whereas TNFR1/ cells showed
similar responses to WT. Inhibition of ERK1/2 diminished TNF-
induced DNA synthesis in WT and TNFR1/ cells. Differences in
TNF-induced STAT3/DNA binding activity and not NFB and
AP-1 transcriptional activation correlated with impaired collagen
accumulation/TIMP-1 induction inTNFR2/ cells. Constitutively
active STAT3 rescued TIMP-1 expression in TNFR2/ cells. We
conclude that TNF and IGF-Imay additively contribute to fibrosis
during intestinal inflammation. TNFR2 is a primary mediator of
fibrogenic actions of TNF acting through ERK1/2 to stimulate
proliferation and through STAT3 to stimulate TIMP-1 and inhibit
collagen degradation.
Fibrosis is a major and serious complication of Crohn’s disease, an
incurable, chronic inflammatory disease of the gastrointestinal tract.
Fibrosis results from an imbalance between synthesis and degradation
of collagen and other extracellular matrix components, ultimately lead-
ing to increased netmatrix accumulationwithin the bowel wall. Fibrosis
is thought to be an overactive, irreversible wound-healing response to
chronic inflammation (1) and can lead to the serious complications of
stricture, bowel narrowing and/or obstruction. In the normal intestine,
subepithelial myofibroblasts, and fibroblasts in the submucosa, inter-
muscle connective tissue of the muscularis propria, and serosa are the
primary sites of collagen mRNA and protein expression (2, 3). In intes-
tine of patients with Crohn’s disease, myofibroblasts are increased in
number in all bowel layers and colocalize with sites of type I collagen
mRNA expression and collagen deposition (2). These results suggest
that myofibroblasts are cellular mediators of intestinal fibrosis in
Crohn’s disease. Wound healing and fibrosis in other organs also
involves myofibroblasts (4–6).
Tumor necrosis factor  (TNF)2 is a central mediator of chronic
inflammatory diseases including Crohn’s disease, as evidenced from
clinical studies reporting a dramatic improvement in Crohn’s patients
treated with infliximab (Remicade; Centocore, Inc.), a neutralizing
monoclonal antibody against TNF (7, 8). The role of TNF in inflam-
mation-induced fibrosis appears complex because available evidence
suggests that TNF regulates collagen synthesis in a tissue-specific
manner. In hepatic stellate cells during liver injury, several studies indi-
cate anti-fibrogenic actions of TNF via inhibition of collagen 1(I)
gene expression (9–12). However, increasing evidence indicates TNF
as a mediator of inflammation-induced fibrosis in other systems. Mice
deficient in either the 55- (TNFR1) or 75-kDa (TNFR2) TNF receptor
show reduced experimentally induced pulmonary fibrosis (13) or renal
fibrosis (14). The reduced pulmonary fibrosis in TNF receptor null mice
occurred despite similar increases in type I collagen gene expression as
wild-type mice, but was accompanied by attenuated induction of tissue
inhibitor of metalloproteinase-1 (TIMP-1) mRNA (13). TIMP-1 is an
inhibitor of matrix metalloproteinases (MMPs) that cleave various
components of the extracellular matrix and therefore reduces collagen
degradation. These findings in TNFR null mice suggest that TNF nor-
mally plays a role in up-regulation of TIMP-1 during lung injury and
may promote fibrosis by inhibiting collagen degradation. However, one
complication in these in vivo studies is that direct effects of TNF recep-
tor knock-out on fibrosis could not be separated from effects on inflam-
mation and the receptor mediating TNF action on fibrosis was not
defined.
Little is known about the role of TNF in inflammation-induced
intestinal fibrosis. Given the key role of TNF as a mediator of Crohn’s
disease as evidenced by the therapeutic benefits of TNF inhibitors, and
the fact that fibrosis is a common and serious problem in Crohn’s dis-
ease, defining the role of TNF in inflammation-induced intestinal
fibrosis is of considerable clinical significance. Because it is difficult to
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distinguish direct effects of TNF on intestinal fibrosis in vivo from
those secondary to effects on inflammation, this study utilized cultured
intestinalmyofibroblasts, cells believed to bemajor cellularmediators of
fibrosis, to determine TNF action and its mechanism of action on
collagen accumulation and proliferation.
Although TNFR1 is regarded as the primary signaling receptor for
systemic TNF inflammatory responses (15, 16), TNFR2 may mediate
TNF effects in a paracrine or autocrine manner because it is strongly
activated bymembrane-boundTNF (17). Evidence for distinct roles of
TNFR1 and TNFR2 in intestinal inflammation has recently started to
emerge. In patients with Crohn’s disease, lamina propria T cells show
increased levels of TNFR2 and not TNFR1 (18). TNFR2 expression is
increased in colonic epithelial cells in human inflammatory bowel dis-
ease and in mouse models of colitis (19). SCID mice reconstituted with
T cells overexpressing TNFR2 show enhanced and accelerated develop-
ment of colitis (18). Although these data indicate a role of TNFR2 in
intestinal inflammation, the roles of TNFR1 and TNFR2 in intestinal
fibrosis are not well defined. This study utilized cultured intestinalmyo-
fibroblasts isolated from TNFR1/, TNFR2/, and TNFR1/2/
mice to determinewhichTNF receptormediates pro-fibrogenic actions
of TNF.
Considerable evidence points to a role of IGF-I as amediator of fibro-
sis in the intestine. Increased local expression of IGF-I mRNA occurs in
all layers of inflamed or fibrotic intestine of Crohn’s disease patients but
not in healthy portions of intestine from the same patients (2, 20, 21).
Local expression of IGF-ImRNA is increased inmultiple animalmodels
of intestinal inflammation (22–25). Increased IGF-I expression is local-
ized to myofibroblasts and smooth muscle cells at sites of increased
collagen mRNA expression and fibrosis in intestine of Crohn’s disease
patients and animalmodels of chronic enterocolitis (2, 22, 23, 26). IGF-I
stimulates collagen protein synthesis and proliferation of enteric
smooth muscle cells (26) and intestinal myofibroblasts in vitro and in
vivo (27–29). Together, these data indicate that locally expressed, mes-
enchymal cell-derived IGF-I contributes to inflammation-induced
intestinal fibrosis. However, the possibility that IGF-I interacts with
TNF to regulate collagen synthesis or proliferation in intestinal myo-
fibroblasts has not been previously tested. This study utilized intestinal
myofibroblasts isolated as a simple system to define whether TNF
affects collagen synthesis and proliferation and if there are interactions
between TNF and IGF-I. We provide novel evidence that TNF
increases collagen accumulation and has mitogenic effects in intestinal
myofibroblasts and that these effects are mediated via the TNFR2. We
also show that TNF has additive effects with IGF-I on collagen accu-
mulation and proliferation and that TNFR2 is essential for these
responses. Finally, we demonstrate that the lack of mitogenic and fibro-
genic actions in TNFR2/ cells are associated with altered ERK1/2 and
STAT3 activation, respectively.
EXPERIMENTAL PROCEDURES
Materials—Mouse recombinant TNF was purchased from Pepro-
tech (Rocky Hill, NJ) and recombinant human IGF-I from Genentech
(San Francisco, CA). Rabbit polyclonal antibody specific for procollagen
1(I) was purchased from Rockland Immunochemicals (Gilbertsville,
PA); rabbit polyclonal antibody to actin from Sigma; peroxidase-conju-
gated donkey anti-rabbit from Jackson ImmunoResearch Laboratories
(West Grove, PA); phospho-ERK1/2 and total ERK1/2 from Santa Cruz
(Santa Cruz, CA); enhanced chemiluminescence (ECL) reagent from
PerkinElmer Life Sciences; goat anti-rabbit secondary antibody conju-
gated to an infrared dye (IR Dye 800 Conjugated Anti-rabbit IgG) from
Rockland; [3H]thymidine and [32P]UTP from Amersham Biosciences;
and STAT3 consensus gel shift oligonucleotides from Santa Cruz.
Mice—Wild-type (WT), TNFR1/ (TNFR1a), and TNFR2/
(TNFR1b) mice on the inbred C57BL/6 background were purchased
fromThe Jackson Laboratory (BarHarbor,ME).WT andmice deficient
in both TNFR1 and TNFR2 signaling (TNFR1/2/; TNFR1a/b) on the
mixed C57BL/6/129S background were also purchased from The Jack-
son Laboratory. No differences were noted between wild-type cells of
the pure C57BL/6 background and the mixed C57BL/6/129S back-
grounds in any of the experiments, and therefore data from both wild-
type strains were pooled. Mice on the inbred C57BL/6 background
expressing a transgene comprising the basal promoter of the murine
procollagen 1(I) collagen gene (3122 to 111 relative to the tran-
scription start site) and two upstreamDNase-sensitive sites that appear
to be important for maximal cell-specific expression linked to the GFP
transgene were derived as previously described (30). Separate cell lines
were isolated from three mice of each genotype for use in subsequent
studies.
Isolation of Intestinal Myofibroblasts—Intestinal myofibroblasts
from adult (40–50-day-old) WT, TNFR1/, TNFR2/, TNFR1/
2/, and collagen-GFP transgenic mice were isolated and cultured as
described previously (31). Myofibroblast phenotype was confirmed
based on positive expression for vimentin and-smoothmuscle actin as
evaluated by Western immunoblot (32, 33). Subconfluent cells were
studied at passages 3–8. Verification of TNF receptor knock-out was
determined byWestern immunoblot analysis using polyclonal anti-rab-
bit TNFR1 or TNFR2 antibodies from Santa Cruz Biotechnology (Santa
Cruz, CA) and compared with WT cells that express both TNF recep-
tors (data not shown).
Assays of Cell Proliferation—Incorporation of [3H]thymidine into
DNAwas used as ameasure of cell proliferation by IGF-I (10 ng/ml) and
TNF (5 ng/ml) alone or in combination. Serum-deprived cells were
incubated with [3H]thymidine (2 Ci/ml) and peptide for 18 h. After
incubation, medium was aspirated, cells were washed with 1 PBS and
fixed with 10% trichloroacetic acid. Total cell extracts were collected in
0.2 N NaOH and 0.1% SDS. Radioactivity incorporated into DNA was
quantified by scintillation counting. All assays were performed in trip-
licate and repeated in at least three separate experiments.
Western Immunoblot for Procollagen 1(I)—Serum-deprived intesti-
nal myofibroblasts were treated with 5 ng/ml TNF or 10 ng/ml IGF-I
alone or in combination for 48 h. Doses were determined as maximal in
separate dose-response experiments (data not shown). Cells were solu-
bilized in Laemmli’s 2 SDS sample buffer and whole cell lysates were
analyzed for procollagen 1(I) protein abundance and actin (loading
control) as previously described (32).
In-cell Western for Collagen for Procollagen 1(I)—An in-cell West-
ernmethod was also utilized in these studies tomonitor for procollagen
1(I) accumulation in a subset of experiments. This method provides a
highly sensitive and rapid system to assay collagen accumulation and
was validated as providing comparable data toWestern immunoblots in
WT cells. Intestinal myofibroblasts isolated from ileum of WT,
TNFR1/, TNFR2/, and TNFR1/2/ mice were plated in an equal
number in a 24-well culture plate. Serum-deprived cells were treated
with IGF-I (10 ng/ml) and TNF (5 ng/ml) alone or in combination for
48 h. Culture medium was removed by aspiration and cells were fixed
with 4% formaldehyde in PBS for 20 min at room temperature. Cells
were washedwith 1 PBS containing 0.1%Triton X-100 and blocked in
0.1% casein and 0.2 PBS solution. Cells were incubated with a procol-
lagen 1(I) primary antibody, washed with 1 PBS containing 0.1%
Tween 20, and incubated with a secondary antibody conjugated to an
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infrared dye (IR dye 800 conjugated anti-rabbit IgG). Plates were
scanned to visualize signal using the Odyssey Infrared Imaging System
(Li-Cor Biosciences, Lincoln, NE) in the 800-nm fluorescent channel.
Signal was quantified using Odyssey Infrared Imaging System Applica-
tion Software version 1.2 (Li-Cor Biosciences). Plates were reprobed for
-tubulin protein and signal was visualized in the 680-nm fluorescent
channel to verify equal cell number across wells.
Collagen Gene Transcription Monitored by Activation of a Procolla-
gen 1(I) Promoter-GFP Reporter Gene—Myofibroblasts isolated from
mice expressing the collagen-GFP transgene were treated with increas-
ing doses of IGF-I and TNF alone or in combination for 24 h. Whole
cell lysates were collected in GFP protein buffer (50 mM NaH2PO4, 10
mM Tris-HCl, 200 mMNaCl, pH 8.0). 500 g of protein was assayed for
GFP fluorescence using the SPEX Fluorolog-3 Research T-format Spec-
trofluorometer at excitation of 488 nm and emission of 510 nm. GFP
fluorescent units were normalized to total protein assayed as a measure
of procollagen 1(I) gene activation.
Total RNA Extraction and Northern Blot Hybridization Assays—To-
tal RNAwas extracted using TRIzol reagent (Invitrogen). Northern blot
hybridization was performed as previously described (34). A TIMP-1
probe was generated by PCR using primers (sense: 5-CCACGAAT-
CAACGAGACC-3 and antisense: 5-CCAAGTGCACAAGCCTAG-
3) with the addition of a T7 RNA polymerase site 5 to the antisense
primer. The PCR product was used as a complementary DNA template
to generate a [32P]UTP-labeled probe using T7 RNA polymerase. To
account for minor variations in RNA loading across samples, blots were
reprobed for human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA using an antisense RNA probe prepared from a com-
mercially available DNA template (Ambion Inc., Austin, TX). Blots
were scanned on a PhosphorImager (Amersham Biosciences Storm
840) and abundance of specific RNAswas quantified using ImageQuant
software forMacintosh. The abundance of TIMP-1mRNAwas normal-
ized to the abundance of GAPDH mRNA in each sample.
Assays of Collagen Synthesis and Degradation—Collagen synthesis
and degradation using radioactive proline was performed as previously
described with some modifications (35). Intestinal myofibroblasts were
incubated for 15 min at 37 °C with serum-free medium supplemented
with 0.1 mM -aminopripionitrile and fresh 10 mM ascorbate to stimu-
late collagen expression. Cells were then pulsed with 100 Ci/ml
[5-3H]proline for 24 h during which [5-3H]proline was incorporated
into synthesized protein. The media containing the [5-3H]proline was
removed, cells were rinsed with 1 PBS and incubated with serum-free
media containing cold 10 mM proline for 24 h during which [5-3H]pro-
line incorporated into protein was released as these proteins are
degraded. Cells were treated with TNF at the start of the pulse and the
start of the chase and compared with no treatment control cells to
determine TNF effects on collagen synthesis and degradation. Collec-
tionswere obtained at 3, 8, and 24 after the start of the pulse and 1, 3, and
24 h after the start of the chase. After the desired incubation period, the
media was collected and cells were lysed in 0.11 M NaCl and 0.05 M
Tris-HCl (pH 7.4). Lysates were centrifuged at 1,000  g for 5 min at
4 °C, and the supernatant was added to the media collected. Cell pellets
were resuspendedwith 0.4 MNaCl and 0.1 MHepes (pH 7.2). Proteins in
the cell lysates and media collections were precipitated with trichloro-
acetic acid and centrifuged 1,000 g for 5min at 4 °C. The protein pellet
was dissolved in 0.2 M NaOH and aliquotted into two tubes. One tube
was treated with 15 g/ml purified Clostridium histolyticum collagen-
ase (Advance Biofactures, Lynbrook, NY) at 37 °C for 2 h, whereas the
other tubewas untreated. The collagenase specifically degrades collagen
protein, thereby releasing [3H]proline incorporated into collagen pro-
tein only. Proteins were precipitated with trichloroacetic acid and cen-
trifuged. Radioactivity in the supernatant fraction was measured by
scintillation counting. To determine radioactivity incorporated in col-
lagen, the radioactivity in the untreated aliquot was subtracted from
radioactivity in the aliquot treated with the collagenase. Assays were
performed in duplicate.
Gelatin Zymography—A gelatinase zymography that quantitates
activity of MMP-2 and MMP-9 was used as an indirect measure of
TIMP-1 activity because TIMP-1 is known to inhibit these enzymes in
other systems. Conditioned media of myofibroblasts treated with or
without TNF for 16 h was collected, concentrated 4 times, and mixed
with the same volume of Laemmli’s 2 SDS sample buffer without
reducing agent. Samples were incubated for 20min at 37 °C and subject
to SDS-PAGE on 8.5% polyacrylamide gels containing 0.1% gelatin. Gels
were soaked in 50 mM Tris-HCl (pH 7.5) containing 2.5% Triton X-100
for 30 min, incubated in buffer containing 50 mM Tris-HCl, 150 mM
NaCl, 10 mM CaCl2, and 0.5 mM ZnCl2 (pH 7.5) for 16 h at 37 °C, and
stained with 0.1% Coomassie Blue R-250. Intensity of gelantinolytic
bands was quantified using NIH Image software (version 1.61).
ERK1/2 Activation and Role in TNF-induced Intestinal Myofibro-
blast Proliferation—Western immunoblot assays were used to monitor
activation of ERK1/2. Serum-deprived cells were treated with 5 ng/ml
TNF for 30, 60, and 180 min. Because maximal activation of ERK1/2
occurred after 30 min of treatment, subsequent experiments were per-
formed at this time point. EGF treatment (10 ng/ml) was used as a
positive control. An ERK1/2-specific inhibitor, PD98059 (Calbiochem,
La Jolla, CA), was used to determine whether TNF-induced [3H]thy-
midine incorporation into DNA of WT and TNFR1/ myofibroblasts
was dependent on ERK1/2 signaling. Serum-deprived cells were treated
with various concentrations of PD98059 for 30 min and subsequently
treated with TNF (5 ng/ml) for 18 h. Incorporation of [3H]thymidine
into DNA was assayed as described above.
NFB and AP-1 Activation—Adenovirus based NFB-luciferase and
AP-1-luciferase reporter constructs were used to monitor NFB
(Ad.NFBLuc) and AP-1 (Ad.AP-1Luc) activation, twomajor pathways
linked to TNF action and potentially to fibrogenic actions of TNF.
Both Ad.NFBLuc (constructed by John F. Engelhardt, The University
of Iowa, Iowa City, IA) and Ad.AP-1Luc (constructed by Drs. Paul B.
McCray andHong Peng Jia, The University of Iowa, Iowa City, IA) were
generous gifts of Dr. Scott H. Randell (University of North Carolina,
Chapel Hill, NC). The Ad.NFBLuc adenoviral construct contains the
firefly luciferase gene driven by four tandem copies of the NFB con-
sensus sequence linked to a TATA-like promoter from the herpes sim-
plex virus-thymidine kinase gene (36, 37). The Ad.AP-1Luc was con-
structed as previously described (38, 39) and contains the firefly
luciferase gene driven by six tandem copies of the AP-1 enhancer
sequence fused to aTATAbox promoter from the herpes simplex virus-
thymidine kinase gene. Intestinal myofibroblasts were infected with
recombinant adenoviral constructs at amultiplicity of infection ranging
from1,000 to 1,500 particles/cell in serum-freemedia (Dulbecco’smod-
ified Eagle’s medium supplemented with 100 units/ml penicillin and 5
g/ml transferrin). Virus was removed 24 h post-infection and cells
were treatedwith various concentrations of TNF and IGF-I alone or in
combination for 8 h. Cells were harvested in Cell Culture Lysis Reagent
(Promega) and samples were stored at 20 °C until assayed. 10 g of
total protein from each sample was measured for luciferase expression
using the LUMIstar Galaxy microplate luminometer (BMG Labtech-
nologies, Durham, NC) with a dual injector system, in which one injec-
tor delivers assay buffer (25 mM glycylglycine, 15 mM KPO4, 15 mM
MgSO4, 4 mM EGTA, 2 mMATP, and 1mM dithiothreitol added before
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use) and the other injector delivers 1 mM D-luciferin (Sigma). All assays
were performed in triplicate.
STAT3 Activation and Role in TNF-induced TIMP-1 Expression—
Electromobility shift assays were used to monitor STAT3 activation by
TNF as previously described (40). Nuclear protein extracts were iso-
lated from serum-deprived intestinal myofibroblasts treated with 5
ng/ml TNF for 60min. 20g of nuclear protein were assayed for DNA
binding to 32P-labeled, double-stranded oligonucleotides correspond-
ing to a consensus STAT3 response element binding site (Santa Cruz).
Oligonucleotides corresponding to a nonconsensus STAT3 response
element binding site (5-TGCTTCCTGGACAGATC-3) located in the
TIMP-1 promoter (41) were obtained from Integrated DNA Technol-
ogies (Coralville, IA).
Serum-deprived cells were infected with constitutively active STAT3
adenovirus (Ad5STAT3C), which contains mutations C661A and
C663Nallowing activation of STAT3without phosphorylation atTyr705
(42), at anmultiplicity of infection of 50, whichwas optimal formaximal
infection as determined by Western immunoblot for STAT3 protein
expression. Virus was removed 24 h post-infection and cells were
treated with 5 ng/ml TNF for 16 h. Total RNA was extracted using
TRIzol reagent and Northern blot hybridization for TIMP-1 expression
was performed as described above.
FIGURE 1. TNF increases DNA synthesis, collagen accumulation, and TIMP-1 expression in intestinal myofibroblasts and acts additively with IGF-I. A, -fold stimulation of
[3H]thymidine incorporation by IGF-I (10 ng/ml) and TNF (5 ng/ml) alone or in combination relative to no treatment controls measured in the same assay. B, representative Western
immunoblots for procollagen 1(I) and actin (control) protein in cells treated with IGF-I (10 ng/ml), TNF (5 ng/ml), or IGF-I  TNF. Histograms show mean  S.E. C, increasing
concentrations of IGF-I or TNF alone or in combination were used to determine whether activation of the procollagen 1(I) promoter showed a dose-dependent response to either
factor. Histograms showing mean  S.E. of the -fold stimulation of GFP fluorescence per g of protein relative to no treatment controls. D, representative Northern blots showing
TIMP-1 and GAPDH (control) mRNA abundance in total RNA isolated from cells treated with IGF-I (10 ng/ml), TNF (5 ng/ml), or IGF-I  TNF. Histograms show mean  S.E. a, p  0.05
versus no treatment; b, p  0.05 versus IGF-I or TNF alone. n  5 per treatment group.
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Statistical Analyses—Values are expressed as mean  S.E. Compar-
isons between treatments in WT cells were analyzed by one-way anal-
ysis of variance for significant effects of treatments versus control, fol-
lowed by planned pairwise comparisons. Comparisons between
treatments and TNFR genotype were analyzed by two-way analysis of
variance for significant effects of treatment or genotype, and a signifi-
cant interaction between treatment and genotype, which provides sta-
tistical evidence for an effect of genotype on the response to TNF.
Subsequent pairwise comparisons used Tukey’s post-hoc test to test for
significant differences between two particular groups. A p value  0.05
was considered statistically significant in all analyses.
RESULTS
TNF IncreasesDNASynthesis, CollagenAccumulation, andTIMP-1
Expression in IntestinalMyofibroblasts andActs Additively with IGF-I—
We have previously shown that IGF-I induces cell proliferation and
procollagen1(I) protein accumulation in cultured intestinalmyofibro-
blasts (32), however, the effects of the proinflammatory cytokine TNF
were unknown. [3H]Thymidine incorporation into DNAwas assayed to
determine whether TNF hadmitogenic effects on intestinal myofibro-
blasts. TNF alone increased DNA synthesis compared with no treat-
ment controls (Fig. 1A). IGF-I and TNF had an additive effect onDNA
synthesis when given in combination (Fig. 1A). Both IGF-I and TNF
treatment induced collagen protein accumulation in intestinal myofi-
broblasts compared with no treatment controls (Fig. 1B). IGF-I and
TNF had an additive effect on collagen accumulation when given in
combination (Fig. 1B).
Intestinal myofibroblasts isolated from ileum of mice expressing the
GFP transgene linked to the procollagen 1(I) promoter were used to
determine whether the increased collagen protein accumulation by
IGF-I and TNF was because of changes in gene transcription. GFP
reporter expression was assayed as a measure of procollagen promoter
activation in total protein extracted from cells treated with increasing
doses of IGF-I or TNF alone or in combination. IGF-I stimulated pro-
collagen promoter activation in a dose-dependent manner, whereas
TNF had no significant effect (Fig. 1C). Procollagen promoter activa-
tion in cells treated with TNF and IGF-I in combination was similar to
levels observed with IGF-I alone (Fig. 1C). These data indicate that the
effects of IGF-I, but not TNF, on collagen accumulation involve tran-
scriptional activation of the procollagen 1(I) gene.
To determine whether the increased collagen protein accumulation
in response to TNF and/or IGF-I was because of post-transcriptional
FIGURE 2. TNF decreases collagen degrada-
tion and MMP-2 activity in intestinal myofibro-
blasts. A, effect of TNF treatment (5 ng/ml) com-
pared with no treatment (No Tx) on incorporation
of [3H]proline into collagen protein (pulse) as a
measure of collagen synthesis and following addi-
tion of non-radioactive proline (chase) as a meas-
ure of collagen degradation. Dashed box indicates
the area of enlarged inset showing decreased col-
lagen degradation with TNF treatment between
the 1- and 3-h chase time points. a, p  0.05 versus
No Tx; n  4 per treatment group. B, gelatin
zymography showing effect of TNF treatment on
MMP-2 activity. a, p  0.05 versus No Tx; n  3 per
treatment group.
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alterations in collagen protein, TIMP-1 mRNA abundance was assayed
from total RNA isolated from cultured intestinal myofibroblasts treated
with IGF-I, TNF, or IGF-I  TNF. We assayed TIMP-1 because it is
increased during Crohn’s disease and in animal models of intestinal
inflammation (43–46). TNF, but not IGF-I, caused a 2.5-fold induc-
tion of TIMP-1 mRNA expression (Fig. 1D). Effects of TNF given in
combination with IGF-I on TIMP-1 mRNA were similar to those
observed with TNF alone (Fig. 1D).
TNF Decreases Collagen Degradation and MMP-2 Activity in
Intestinal Myofibroblasts—Compared with no treatment controls,
TNF treatment caused no change in the rate of collagen synthesis,
as measured by [3H]proline incorporation into collagen protein (Fig.
2A). Compared with untreated controls, TNF treatment decreased
the rate of collagen degradation during the chase with cold proline,
which was particularly evident at early time points during the chase
with cold proline, resulting in less collagen degradation in the sam-
FIGURE 3. TNFR2 and ERK1/2 activation are essential for TNF-stimulated DNA synthesis in intestinal myofibroblasts. A, -fold stimulation of [3H]thymidine incorporation into
DNA by IGF-I (10 ng/ml) and TNF (5 ng/ml) alone or in combination. a, p  0.05 versus no treatment; b, p  0.05 versus IGF-I or TNF alone. n  four separate experiments done in
triplicate. B, representative Western immunoblots showing pERK1/2, total ERK1/2, and control -tubulin protein from total protein isolated from cells treated with TNF (5 ng/ml) or
EGF (10 ng/ml; positive control) for 30 min. Histograms show mean  S.E. a, p  0.05 versus no treatment; n  4 per treatment group. C, TNF induction of [3H]thymidine incorporation
into DNA of WT and TNFR1/ cells is inhibited in a dose-dependent manner by PD98059, an ERK1/2 inhibitor. a, p  0.05 versus no treatment; b, p  0.05 versus TNF; n  6 per
treatment. TNF-induced activation of ERK1/2 is inhibited by PD98059 as shown in the representative Western immunoblots.
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ples treated with TNF compared with no treatment at the end of a
24-h chase period.
Gelatinolytic activity of conditionedmedia from intestinal myofibro-
blasts treated with TNF was assessed by gelatin zymography. Gelati-
nolytic bands of 62 kDa corresponding to MMP-2 activity were
decreased in a dose-dependent manner by TNF (Fig. 2B). Activity of
MMP-9 was variable and showed no significant change with TNF
treatment (data not shown).
TNFR2 and ERK1/2 Activation Are Essential for TNF-stimulated
DNA Synthesis in Intestinal Myofibroblasts—Intestinal myofibroblasts
isolated from ileum of WT, TNFR1/, TNFR2/, and TNFR1/2/
mice were used to determine which TNF receptor mediates TNF
induction of DNA synthesis. TNFR1/2/ myofibroblasts were used as
a negative control because they are deficient in TNF signaling. IGF-I
and TNF alone increased DNA synthesis and showed an additive
response in WT and TNFR1/ myofibroblasts when given in combi-
nation (Fig. 3A). In TNFR2/ and TNFR1/2/ cells, IGF-I but not
TNF increased DNA synthesis. In TNFR2/ and TNFR1/2/ cells,
effects of IGF-I andTNF given in combination onDNA synthesis were
similar to that of IGF-I treatment alone (Fig. 3A). Collectively, these
results indicate that TNFR2 is essential for TNF-induced DNA syn-
thesis in intestinal myofibroblasts.
Western immunoblot analyses revealed activation of ERK1/2 by
TNF and EGF, which was used as a positive control. The effect of
TNF was absent in TNFR2/ and TNFR1/2/ cells, but was
retained in TNFR1/ cells (Fig. 3B). Induction of p38MAPK and c-Jun
NH2-terminal kinase was unaffected by TNFR2/ deletion (data not
shown). To determine whether TNF-induced cell proliferation, as
measured by DNA synthesis, is dependent on ERK1/2 signaling, WT
and TNFR1/ cells were treated with PD98059, an ERK1/2-specific
inhibitor, for 30 min prior to treatment with TNF. TNF-stimulated
[3H]thymidine incorporation into DNA in WT and TNFR1/ cells in
the absence of PD98059 (Fig. 3C). PD98059 inhibited TNF-stimulated
[3H]thymidine incorporation into DNA in a dose-dependent manner
(Fig. 3C). PD98059 inhibited TNF-stimulated ERK1/2 activation as
shown by Western immunoblot from protein extracts isolated from
WT and TNFR1/ cells treated in replicate with the [3H]thymidine
incorporation assay (Fig. 3C, bottom panel). These results indicate that
TNF-induced DNA synthesis in intestinal myofibroblasts is depend-
ent on ERK1/2 signaling.
TNFR2 Is Essential for TNF Induction of Collagen Protein
Accumulation—Intestinal myofibroblasts isolated from ileum of WT,
TNFR1/, TNFR2/, and TNFR1/2/ mice were used to determine
whether TNFR2 also mediates TNF-induced procollagen 1(I) pro-
tein accumulation in these cells. IGF-I and TNF increased procollagen
1(I) protein in WT and TNFR1/ myofibroblasts (Fig. 4). IGF-I, but
not TNF, increased procollagen 1(I) protein in TNFR2/ and
TNFR1/2/ cells. Similarly, IGF-I and TNF had an additive effect on
collagen accumulation inWT and TNFR1/ cells, but the response in
TNFR2/ andTNFR1/2/ cells was similar to that of IGF-I treatment
alone (Fig. 4). Subsequent staining with -tubulin ensured even plating
of cells across wells (data not shown). Collectively, these results indicate
FIGURE 4. TNFR2 is essential for TNF induction
of collagen protein accumulation. A, represent-
ative in-cell Western blot showing WT, TNFR1/,
TNFR2/, or TNFR1/2/ myofibroblasts plated
in an equal number in a 24-well culture plate and
treated with IGF-I (10 ng/ml) and TNF (5 ng/ml)
alone or in combination. B, histograms showing
mean  S.E. of the -fold induction relative to no
treatment controls of the same genotype. a, p 
0.05 versus no treatment (No Tx); b, p  0.05 versus
IGF-I or TNF alone. n  three separate experi-
ments done in duplicate.
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that TNFR2 is essential for TNF action on collagen protein accumu-
lation in intestinal myofibroblasts.
TNF-induced TIMP-1 mRNA Expression Is Mediated by TNFR2—
To determine whether the diminished effect of TNF on collagen pro-
tein accumulation in TNFR2/ myofibroblasts was linked to attenu-
ated TIMP-1 induction, TIMP-1 mRNA abundance was measured in
WT, TNFR1/, and TNFR2/ cells. TNF, alone or in combination
with IGF-I, increased TIMP-1 expression in WT and TNFR1/ myo-
fibroblasts but no significant induction of TIMP-1 was observed in
TNFR2/ cells (Fig. 5). Therefore, TNFR2 is necessary for TNF-
mediated induction of TIMP-1mRNA as well as collagen accumulation
in intestinal myofibroblasts.
NFB or AP-1 Pathways Do Not Account for Diminished Collagen
Accumulation in TNFR2/ Cells—Collagen accumulation stimulated
by TNF was not affected by PD98059, an ERK1/2-specific inhibitor, as
measured by in-cell Western blots (data not shown), which suggested
that TNF-induced collagen accumulation, in contrast to proliferation,
is not dependent on ERK1/2 signaling. Transcriptional activation of
NFB and AP-1 was therefore assessed because both NFB and AP-1
are the two major transcription factors activated by TNF (47). Intesti-
nal myofibroblasts were infected with an adenovirus expressing an
NFB (Ad.NFBLuc) or AP-1 (Ad.AP-1Luc) responsive luciferase
reporter gene and treated with TNF, IGF-I, or TNF and IGF-I in
combination.WTmyofibroblasts show increased NFB transcriptional
activation with TNF treatment but no effect by IGF-I treatment (Fig.
6A). TNFR1/ and TNFR2/ myofibroblasts show increased NFB
transcriptional activation by TNF only at the higher dose, but this
response is diminished compared withWT cells (Fig. 6A). As a negative
control, TNFR1/2/ myofibroblasts show complete ablation of NFB
transcriptional activity by TNF. Cells treated with TNF and IGF-I in
combination show similar NFB transcriptional activation as TNF
treatment alone. Collectively, these results suggest in the absence of
either TNF receptor, that TNF-induced transcriptional activity of
NFB is reduced comparedwithWT.However, because onlymyofibro-
blasts lacking functional TNFR2 but not cells lacking functional TNFR1
show diminished TNF-induced collagen protein and TIMP-1 mRNA,
the diminished NFB activation cannot account for this difference
between TNFR1/ and TNFR2/ cells.
As shown in Fig. 6B, WT cells show increased AP-1 transcriptional
activity when treated with IGF-I and the higher dose of TNF.
TNFR1/ and TNFR2/ myofibroblasts show similar activation of
AP-1 transcription by TNF and IGF-I asWT cells, indicating the func-
tional loss of one TNF receptor can be compensated for by the other
TNF receptor in terms of AP-1 transcriptional activity. TNFR1/2/
myofibroblasts showed similar activation ofAP-1 transcription by IGF-I
as the other genotypes, but showed no induction of AP-1 transcription
by TNF, as expected because these cells are devoid of TNF signaling
(Fig. 6B). Collectively, these results suggest that diminished TNF-in-
duced collagen protein accumulation and TIMP-1 expression in
TNFR2/ myofibroblasts compared withWT andTNFR1/ cells are
not associated with decreased AP-1 transcriptional activation.
STAT Activation Is Altered in TNFR2/ Cells and Expression of
Constitutively Active STAT3 Is Sufficient to Rescue TNF-induced
TIMP-1 Expression in TNFR2/ Cells—Emerging evidence in other
cell types indicate cross-talk between TNF-activated pathways and
JAK-STAT pathways (48–50). Electromobility shift assays using a
radiolabeled consensus DNA binding site for STAT3 showed that
TNF induced STAT3 response element binding activity in WT and
TNFR1/ cells (Fig. 7A). In TNFR2/ cells, TNF also induced bind-
ing to the STAT3 consensus sequence but the mobility of this complex
was altered compared with WT and TNFR1/ cells. This binding
could be competed with unlabeled STAT3 oligonucleotides but not
STAT1 (Fig. 7A) or STAT5 oligonucleotides (data not shown). Because
the promoter of the TIMP-1 gene, which is induced by TNF in WT
and TNFR1/ cells but not TNFR2/ cells, contains a nonconsensus
binding site for STAT3 (41), electromobility shift assays were also per-
formed using oligonucleotides corresponding to this binding site. TNF
induced nonconsensus STAT3 response element binding activity in
WT cells but not in TNFR2/ cells (Fig. 7B), suggesting that in
TNFR2/ cells STAT3 binding to the STAT3 response element in the
TIMP-1 promoter is impaired.
To assess directly if STAT3 plays a role in TIMP-1 induction,
TNFR2/ cells were transfected with a constitutively active form of
STAT3 or a control GFP expressing adenovirus. As in previous experi-
ments, TNF failed to induce TIMP-1 in TNFR2/ cells transfected
with the controlGFP adenovirus (Fig. 7C). However, STAT3 adenovirus
infection induced TIMP-1 expression in TNFR2/ cells regardless of
whether cells were treated with TNF (Fig. 7C). This suggests that
activated STAT3 is sufficient to induce TIMP-1 in TNFR2/ cells.
DISCUSSION
TNF is awell establishedmediator of chronic inflammatory diseases
including Crohn’s disease. The role of TNF in inflammation-induced
intestinal fibrosis is not well defined, which could be due, at least in part,
to the difficulty of segregating direct in vivo effects of TNF on fibrosis
from secondary effects of TNF on inflammation. Additionally, very
few mouse models of intestinal inflammation are accompanied with
fibrosis. For this reason, this study used cultured intestinal myofibro-
blasts, cell types thought to mediate fibrosis (2, 51, 52), as a model
system to study direct actions of TNF. Our findings provide novel
information that TNF induces collagen accumulation and has mito-
genic effects in intestinal myofibroblasts, providing important evidence
FIGURE 5. TNF-induced TIMP-1 mRNA expression is mediated by TNFR2. Repre-
sentative Northern blots showing TIMP-1 and GAPDH mRNA abundance in total RNA
isolated from WT, TNFR1/, and TNFR2/ myofibroblasts treated with IGF-I (10
ng/ml), TNF (5 ng/ml), or IGF-I  TNF. Histograms showing mean  S.E. of the -fold
difference relative to no treatment controls of the same genotype. a, p  0.05 versus no
treatment. n  4 per treatment group.
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for pro-fibrogenic actions of TNF in intestine. TNF also had additive
effects on collagen accumulation and myofibroblast proliferation when
combinedwith IGF-I, a growth factor implicated as a key pro-fibrogenic
mediator during intestinal inflammation in vivo (2, 22, 23, 26). Our
studies reveal that additive effects of IGF-I and TNF on total collagen
accumulation are mediated by IGF-I induction of collagen gene tran-
scription and TNF-induced inhibition of collagen degradation via
TIMP-1. Furthermore, IGF-I and TNF additively stimulate intestinal
myofibroblast DNA synthesis, a measure of cell proliferation. Because
these cell types are known to produce collagen, expansion of myofibro-
blasts could also promote fibrosis.
TNFR2 is emerging as a key receptor that is up-regulated in experi-
mental and clinical inflammatory bowel disease (18, 19). Our findings
provide new information that TNFR2 is essential for TNF induction of
DNA synthesis and collagen protein accumulation in intestinal myofi-
broblasts because TNFR2/ and TNFR1/2/ cells showed no
response to TNF compared withWT and TNFR1/ cells. The loss of
TNF-induced collagen accumulation in TNFR2/ cells is associated
with impaired TIMP-1 expression. Importantly, TNFR2/ cells
showed similar stimulation of collagen accumulation and DNA synthe-
sis in response to IGF-I as WT and TNFR1/ cells indicating the lack
of responsewas specific to TNF. Collectively, these results suggest that
TNFR2 rather than TNFR1 is the primary mediator of the pro-fibrotic
effects of TNF in intestinal myofibroblasts.
Much effort has focused on the signaling pathways modulating the
proinflammatory and proapoptotic or anti-apoptotic actions of TNF.
Our studies provide novel information about TNFR1- and TNFR2-
linked pathways leading to increased collagen accumulation and prolif-
eration in intestinal myofibroblasts. ERK1/2 activation was absent in
TNFR2/ cells. Furthermore, the TNF-induced cell proliferation,
but not collagen accumulation, in WT and TNFR1/ myofibroblasts
was blocked by an ERK1/2-specific inhibitor. These results suggest that
TNF-stimulated cell proliferation is dependent on TNFR2 and
ERK1/2 signaling in intestinal myofibroblasts. Luciferase reporter
assays in WT, TNFR1/, TNFR2/, and TNFR1/2/ cells indicate
that both TNF receptor isoforms activate NFB and AP-1, two major
transcription factors known to be activated by TNF in other cell types
(47). However, the substantial NFB and AP-1 activation remaining in
TNFR2/ cells is clearly insufficient to mediate the collagen and
TIMP-1 inducing effects of TNF because these responses were absent
in TNFR2/ cells. Furthermore, NFB activation by TNFwas greatly
attenuated in TNFR1/ cells, yet these cells show preserved collagen
accumulation and TIMP-1 induction by TNF. Examination of other
pathways revealed that in TNFR2/ cells TNF activated the binding
of nuclear proteins to a STAT3 consensus response element, but the
complex differed from the STAT3 binding complex in WT or
TNFR1/ cells. Moreover, TNF-induced binding of nuclear proteins
to a STAT3 nonconsensus response element located in the TIMP-1
FIGURE 6. Diminished collagen accumulation in
TNFR2/ cells is not associated with alter-
ations in NFB or AP-1 transcriptional activa-
tion. Intestinal myofibroblasts were infected with
Ad.NFBLuc virus (A) or Ad.AP-1Luc virus (B) and
treated for 8 h with increasing concentrations of
TNF or IGF-I (ng/ml) as indicated below each
graph. Histograms showing mean  S.E. of the
-fold difference relative to no treatment controls
of the same genotype. a, p  0.05 versus no treat-
ment; b, p  0.05 versus WT of same treatment. n 
6 for WT, TNFR1/, and TNFR2/. n  3 for
TNFR1/2/.
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promoter (41) in WT cells but this response was absent in TNFR2/
cells. Expression of constitutively active STAT3 in TNFR2/ cells was
sufficient to induce TIMP-1 expression. Together these findings indi-
cate that TNFR2 acting via STAT3 rather than the NFB or AP-1 path-
ways typically associatedwithTNFR action is required for and sufficient
to induce TIMP-1, which appears to be the major mediator of TNF-
induced collagen accumulation. Whereas our data demonstrate that
STAT3 can induce TIMP-1 expression in intestinal myofibroblasts and
that TNF stimulates binding to the STAT3 response element in the
TIMP-1 promoter, our studies suggest that more detailed analyses of
the mechanisms by which different TNF receptors link to STAT path-
ways will be of interest in the future. This is because the differentmobil-
ity of protein-DNA complexes binding to a STAT3 consensus element
inTNFR2/ cells versusWTandTNFR1/ cells suggests thatTNFR1
and TNFR2 may couple to different STAT isoforms. Future studies of
whether distinct STAT-coupled pathways are activated by TNFR1 ver-
sus TNFR2 will therefore be of interest.
In summary, our study provides new evidence for additive interac-
tions between TNF and IGF-I on collagen accumulation in intestinal
myofibroblasts and defines themechanisms of action as depicted in Fig.
8. Our data suggest that IGF-I promotes fibrosis by primary effects on
collagen gene transcription to increase collagen synthesis and by stim-
ulating expansion of fibrogenic cells. TNF, acting primarily via
FIGURE 8. Hypothetical model of TNF and IGF-I actions leading to increased colla-
gen accumulation. IGF-I promotes expansion of fibrogenic intestinal myofibroblasts
and stimulates collagen gene transcription to increase collagen synthesis. TNF, acting
primarily via TNFR2, promotes fibrosis by stimulating myofibroblast proliferation in an
ERK-dependent manner and reducing collagen degradation by inducing TIMP-1 via a
STAT3-dependent mechanism. Through these distinct mechanisms TNF and IGF-I addi-
tively increase collagen accumulation.
FIGURE 7. TNF-induced STAT3 response ele-
ment binding is altered in TNFR2/ cells and
constitutively active STAT3 induces TIMP-1 in
TNFR2/ cells. A, electromobility shift assay
showing binding of nuclear proteins from WT,
TNFR1/, and TNFR2/ cells treated with 5
ng/ml TNF to a STAT3 consensus response ele-
ment (RE). Binding is competed by unlabeled
STAT3 oligonucleotides (STAT3 cold) but not
STAT1 oligonucleotides (STAT1 cold). The mobility
of the binding complex in TNFR2/ cells is
altered. B, electromobility shift assay showing
binding of nuclear proteins from WT but not
TNFR2/ cells treated with 5 ng/ml TNF to the
STAT3 nonconsensus response element located in
the TIMP-1 promoter. C, representative Northern
blot showing TIMP-1 and GAPDH mRNA abun-
dance in total RNA isolated from TNFR2/ myofi-
broblasts infected with constitutively active STAT3
(STAT3 Ad) or GFP expressing adenovirus  TNF
(5 ng/ml). Histograms show mean  S.E. of -fold
induction relative to untreated controls. Western
immunoblot showing overexpression of STAT3 in
TNFR2/ cells infected with constitutively active
STAT3 adenovirus.
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TNFR2, promotes fibrosis by stimulating myofibroblast proliferation in
an ERK-dependent manner and reducing collagen degradation by
inducing TIMP-1 via STAT3. Importantly, the distinct mechanisms by
which TNF and IGF-I promote collagen accumulation result in an
additive increase in collagen accumulation. This suggests that therapies
targeted specifically at limiting TNFR2 actions and combined with
inhibitors of IGF-I action may hold promise for limiting fibrosis associ-
ated with intestinal inflammation and Crohn’s disease, for which there
are currently no approved or effective pharmacological therapies. Our
findings of additive interactions of TNF and IGF-I on collagen accu-
mulation in intestinal myofibroblasts also indicate that such interac-
tions may be relevant to mechanisms of fibrosis and therapy develop-
ment in other organ systems.
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